Drug Targets from Genomics: Evolving Tools for Discovery

TABLE OF CONTENTS

CHAPTER 1: EXECUTIVE SUMMARY

Omics and Pharma: The Context

Omics in Pharma R&D Today

Market Implications of R&D Trends

CHAPTER 2: INTRODUCTION

Scope and Nature of this Report

CHAPTER 3: EVOLUTION OF DRUG DISCOVERY

Drug Discovery Pre-Industrialization

The Industrialization of Drug Discovery

The Human Genome Project and the Rise of Omics

Rise of the Personalized Medicine Paradigm

Pharma in the Post-Genomic Era

Omics for Drug Discovery

Transcriptomics

Positional DNA Microrrays

Encoded Bead Arrays

Proteomics

Metabolomics

Target Discovery

Target Validation

Omics for Drug Development

Preclinical Development

Clinical Development

Omics and Systems Biology

CHAPTER 4: OMICS IN PHARMA R&D TODAY

To What Extent Has Genomics Become Embedded in Pharma R&D?

To What Extent Have Omic Technologies Proved Their Value?

How Have Omic Technologies Fared in Target Identification?

To What Extent Has SNP Genotyping Contributed to Target ID?

What Are The Prospects for Omic-Based Toxicity Prediction?

To What Extent Will Omics-Based Patient Stratification Be Practical?

How Do Organizational Factors Play Into The Omics Equation?

CHAPTER 5: MARKET IMPLICATIONS OF R&D TRENDS

Omic-Related Deals Involving Pharma

Market for Omic Technology Products

CHAPTER 6: COMPANY OMICS R&D SUMMARIES

Abbott Laboratories

AstraZeneca PLC

Bristol-Myers Squibb

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline

Merck & Co., Inc.

Millennium Pharmaceuticals

Novartis International AG

Pfizer, Inc.

CHAPTER 7: INTERVIEWS WITH INDUSTRY EXPERTS

Eugene Brown, Ph.D., Senior Director, Molecular Profiling and Biomarker Discovery, Biological Technologies, Wyeth Research Brian Edmonds, Ph.D., Group Leader for Enabling Technologies, Eli Lilly Stephen Naylor, Ph.D., Adjunct Professor of Genetics and Genomics, Boston University School of Medicine Dalia Cohen, Ph.D., Global Head of Functional Genomics, Novartis Institutes for Biomedical Research Anonymous Technology Manager in the Pharmaceuticals Division of a Large Organization with Diverse Product Lines Upper Level Manager in Big Pharma

REFERENCES

TABLE OF EXHIBITS

Exhibit 3.1 The Affymetrix Microarray Assay Process

Exhibit 3.2 The Affymetrix Photolithographic Array Production Process

Exhibit 3.3 Quantum Dot Spectral Properties

Exhibit 3.4 The Aclara eTagR Technology

Exhibit 3.5 High Throughput Genomics Multiplexed Gene Expression Detection Technology

Exhibit 3.6 Ciphergen ProteinChipR Technology

Exhibit 3.7 Ciphergen Biomarker Discovery Technology

Exhibit 3.8 A 2D Gel Illustrating a Typical Protein Electrophorogram

Exhibit 3.9 Applications of Post-Genomic Biomarkers

Exhibit 3.10 Selected Systems Biology Commercial Biomarker Offerings

Exhibit 5.1 Selected Pharmaceutical Omic-Related Deals

Exhibit 5.2 Current and Projected Revenues (2004 and 2009) for Omic Technology Products, By Technology Category

Exhibit 5.3 Current and Projected Revenues (2004 and 2009) for Omic Technology Products, By Market Segment